+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • ID: 5589951
  • Report
  • April 2022
  • Region: Global
  • 207 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • AstraZeneca Plc
  • Chinook Therapeutics Inc
  • Glycadia Inc
  • MediPost Co Ltd
  • Praetego Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Drugs In Development, 2022, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 30, 12, 1, 36 and 8 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • AstraZeneca Plc
  • Chinook Therapeutics Inc
  • Glycadia Inc
  • MediPost Co Ltd
  • Praetego Inc

IntroductionReport CoverageDiabetic Nephropathy - Overview
Diabetic Nephropathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Diabetic Nephropathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Diabetic Nephropathy - Companies Involved in Therapeutics DevelopmentDiabetic Nephropathy - Drug ProfilesDiabetic Nephropathy - Dormant ProjectsDiabetic Nephropathy - Discontinued ProductsDiabetic Nephropathy - Product Development Milestones
Featured News & Press Releases
  • Feb 28, 2022: Goldfinch Bio announces positive preliminary data from phase 2 clinical trial evaluating GFB-887 as a precision medicine for patients with focal segmental glomerular sclerosis (FSGS)
  • Nov 08, 2021: Goldfinch Bio showcases biology, genetic and clinical programs at ASN Kidney Week demonstrating leadership in precision medicines for kidney diseases
  • Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker
  • Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker
  • Sep 01, 2021: XORTX announces grant of European patent supporting diabetic nephropathy
  • Aug 28, 2021: Bayer announces KERENDIA (finerenone) reduces the risk of cardiovascular outcomes in new phase III FIGARO-DKD study in adults with chronic kidney disease (Stages 1-4) associated with type 2 diabetes
  • Aug 17, 2021: Bayer to present late breaking data from Phase III FIGARO-DKD (finerenone) studies
  • Aug 02, 2021: Shanghai Pharmaceuticals SPH3127 tablets new indications received phase II clinical trial approval notice
  • Jul 27, 2021: Goldfinch Bio announces upcoming presentations at the 13th International Podocyte Conference
  • Jun 22, 2021: Caladrius Biosciences to assess its CLBS201 CD34+ cell therapy in diabetic kidney disease
  • May 13, 2021: Goldfinch Bio initiates phase 1 clinical trial of GFB-024, a novel precision medicine product candidate for patients with severe insulin resistant Diabetic Nephropathy (DN)
  • Mar 31, 2021: Mitsubishi Tanabe Pharma wins patent infringement lawsuit of Canagliflozin Hydrate in the U.S. district court
  • Feb 26, 2021: Canagliflozin (TA-7284) has been approved in Taiwan for diabetic nephropathy
  • Sep 21, 2020: New study offers hope for patients with diabetes and advanced kidney disease
  • Sep 08, 2020: Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Diabetic Nephropathy, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Diabetic Nephropathy - Pipeline by Aadi Bioscience Inc, 2022
  • Diabetic Nephropathy - Pipeline by AIBIOS Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Akebia Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by Algomedix Inc, 2022
  • Diabetic Nephropathy - Pipeline by Anagenics Ltd, 2022
  • Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by AptaBio Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, 2022
  • Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, 2022
  • Diabetic Nephropathy - Pipeline by AstraZeneca Plc, 2022
  • Diabetic Nephropathy - Pipeline by Bayer AG, 2022
  • Diabetic Nephropathy - Pipeline by Betagenon AB, 2022
  • Diabetic Nephropathy - Pipeline by Bird Rock Bio Inc, 2022
  • Diabetic Nephropathy - Pipeline by BLR Bio LLC, 2022
  • Diabetic Nephropathy - Pipeline by Boehringer Ingelheim International GmbH, 2022
  • Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Co, 2022
  • Diabetic Nephropathy - Pipeline by Caladrius Biosciences Inc, 2022
  • Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, 2022
  • Diabetic Nephropathy - Pipeline by Certa Therapeutics Pty Ltd, 2022
  • Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, 2022
  • Diabetic Nephropathy - Pipeline by Chinook Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by Corbus Pharmaceuticals Inc, 2022
  • Diabetic Nephropathy - Pipeline by CSL Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Curacle Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by Dimerix Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Frontbio Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Future Medicine Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by GenKyoTex SA, 2022
  • Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, 2022
  • Diabetic Nephropathy - Pipeline by Glycadia Inc, 2022
  • Diabetic Nephropathy - Pipeline by Gmax Biopharm LLC, 2022
  • Diabetic Nephropathy - Pipeline by GNI Group Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Goldfinch Bio Inc, 2022
  • Diabetic Nephropathy - Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Guangzhou Nanxin Pharmaceutical Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Hua Medicine Shanghai Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Inovio Pharmaceuticals Inc, 2022
  • Diabetic Nephropathy - Pipeline by InSilico Medicine, 2022
  • Diabetic Nephropathy - Pipeline by Inversago Pharma Inc, 2022
  • Diabetic Nephropathy - Pipeline by Johnson & Johnson, 2022
  • Diabetic Nephropathy - Pipeline by Landos Biopharma Inc, 2022
  • Diabetic Nephropathy - Pipeline by MediPost Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Merck & Co Inc, 2022
  • Diabetic Nephropathy - Pipeline by Mesoblast Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
  • Diabetic Nephropathy - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Novartis AG, 2022
  • Diabetic Nephropathy - Pipeline by Novo Nordisk AS, 2022
  • Diabetic Nephropathy - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Orbsen Therapeutics Ltd, 2022
  • Diabetic Nephropathy - Pipeline by PhytoHealth Corp, 2022
  • Diabetic Nephropathy - Pipeline by Poxel SA, 2022
  • Diabetic Nephropathy - Pipeline by Praetego Inc, 2022
  • Diabetic Nephropathy - Pipeline by ProKidney LLC, 2022
  • Diabetic Nephropathy - Pipeline by RAGE Biotech Pty Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Reata Pharmaceuticals Inc, 2022
  • Diabetic Nephropathy - Pipeline by Rebus Holdings Inc, 2022
  • Diabetic Nephropathy - Pipeline by Scohia Pharma Inc, 2022
  • Diabetic Nephropathy - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022
  • Diabetic Nephropathy - Pipeline by Serodus ASA, 2022
  • Diabetic Nephropathy - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by siRNAgen Therapeutics Corp, 2022
  • Diabetic Nephropathy - Pipeline by Slate Bio Inc, 2022
  • Diabetic Nephropathy - Pipeline by Sulfateq BV, 2022
  • Diabetic Nephropathy - Pipeline by Unicyte AG, 2022
  • Diabetic Nephropathy - Pipeline by Vidasym Inc, 2022
  • Diabetic Nephropathy - Pipeline by Wuhan Hamilton Bio-technology Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
  • Diabetic Nephropathy - Pipeline by XORTX Therapeutics Inc, 2022
  • Diabetic Nephropathy - Pipeline by ZyVersa Therapeutics Inc, 2022
  • Diabetic Nephropathy - Dormant Projects, 2022
  • Diabetic Nephropathy - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Diabetic Nephropathy, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aadi Bioscience Inc
  • AIBIOS Co Ltd
  • Akebia Therapeutics Inc
  • Algomedix Inc
  • Anagenics Ltd
  • APT Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Betagenon AB
  • Bird Rock Bio Inc
  • BLR Bio LLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • CCRP Therapeutics GmbH
  • Certa Therapeutics Pty Ltd
  • ChemoCentryx Inc
  • Chinook Therapeutics Inc
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • Curacle Co Ltd
  • Daiichi Sankyo Co Ltd
  • DiaMedica Therapeutics Inc
  • Dimerix Ltd
  • Frontbio Co Ltd
  • Future Medicine Co Ltd
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Glycadia Inc
  • Gmax Biopharm LLC
  • GNI Group Ltd
  • Goldfinch Bio Inc
  • Guangdong East Sunshine Pharmaceutical Co Ltd
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Guangzhou Nanxin Pharmaceutical Co Ltd
  • Hua Medicine Shanghai Ltd
  • Inovio Pharmaceuticals Inc
  • InSilico Medicine
  • Inversago Pharma Inc
  • Johnson & Johnson
  • Landos Biopharma Inc
  • MediPost Co Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Nanjing Aimeifei Biomedical Technology Co Ltd
  • Novartis AG
  • Novo Nordisk AS
  • Ono Pharmaceutical Co Ltd
  • Orbsen Therapeutics Ltd
  • PhytoHealth Corp
  • Poxel SA
  • Praetego Inc
  • ProKidney LLC
  • RAGE Biotech Pty Ltd
  • Reata Pharmaceuticals Inc
  • Rebus Holdings Inc
  • Scohia Pharma Inc
  • Secarna Pharmaceuticals GmbH & Co KG
  • Serodus ASA
  • Shanghai Alebund Pharmaceuticals Ltd
  • Shanghai Pharmaceutical Group Co Ltd
  • siRNAgen Therapeutics Corp
  • Slate Bio Inc
  • Sulfateq BV
  • Unicyte AG
  • Vidasym Inc
  • Wuhan Hamilton Bio-technology Co Ltd
  • Wuhan LL Science and Technology Development Co Ltd
  • XORTX Therapeutics Inc
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown